TSS
ELTX icon

Two Sigma Securities’s Elicio Therapeutics ELTX Stock Holding History

Two Sigma Securities’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,459
Closed -$13K – 2746
2022
Q3 		$13K Buy
+1,459
New +$15.2K ﹤0.01% 2356

Other funds holding ELTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Two Sigma Securities's ELTX Position: Q4 2022 in Review

Two Sigma Securities sold out of Elicio Therapeutics (ELTX) in Q4 2022, closing a stake of 1,459 shares — an estimated $13K sold.

Two Sigma Securities first reported a position in ELTX in Q3 2022 and held it in 1 quarter. The position peaked at $13K in Q3 2022. 30 funds tracked by Wall St. Rank hold ELTX as of Q4 2022.

  • Two Sigma Securities reported no remaining Elicio Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Two Sigma Securities sold 1,459 Elicio Therapeutics shares in Q4 2022, an estimated $13K.
  • Two Sigma Securities first reported a position in Elicio Therapeutics in Q3 2022 and held it in 1 quarter.
  • Two Sigma Securities's Elicio Therapeutics position peaked at $13K in Q3 2022.
  • 30 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q4 2022.

Based on Two Sigma Securities's 13F filing for Q4 2022, filed 14 Feb 2023.